Understanding the Recent 6-3 Supreme Court Decision on Agency Deference
July 1, 2024
The recent 6-3 Supreme Court decision in the Loper Bright case overturns the 1984 “Chevron deference” precedent, rejecting the practice of federal courts deferring to governmental agencies on legal interpretations of ambiguous statutory language.
The impact of this ruling is significant as it shifts the balance of power between agencies and the judiciary in interpreting laws and deciding the best ways to apply them. Moving forward, federal courts are likely to engage in a more thorough review of agency interpretations, rule-making and actions.
- This decision, the Supreme Court’s ruling last week rejecting the SEC’s in-house enforcement of securities fraud claims, and the recent decision of the U.S. Fifth Circuit Court of Appeals to vacate the SEC’s Private Fund Adviser Rules, significantly limit the SEC’s reach over private fund advisers. However, this will likely not impact the SEC’s general focus on fiduciary considerations and the duty to disclose actual or potential conflicts of interest in their examinations, investigations, and enforcement sweeps of investment advisers.
The 6-3 decision, along ideological lines, discards a 1984 precedent directing federal courts to defer to agency legal interpretations when the statutory language passed by Congress is ambiguous.
View referenced article
Author(s)
Related Insights
December 4, 2025
Foley Viewpoints
Foley Event Key Takeaways- Ready for Anything: Preparing for IPOs, SPACs, and Unexpected Capital Market Shift
Foley & Lardner, Protiviti and SS&C Intralinks recently hosted an event in Foley’s Silicon Valley office at Palo Alto Center. Moderated by Foley partner Louis Lehot, the session titled "Ready for Anything: Preparing for IPOs, SPACs, and Unexpected Capital Market Shifts," brought together industry leaders: JD Fay (ex-CFO, Matterport, de-SPAC’d and then sold to CoStar Group), Dan Angus (Managing Director, Nasdaq), and Andrea Vardaro Thomas (Managing Director, Protiviti). Their combined experience provided a roadmap for companies facing the volatile and rapidly shifting capital markets of 2026.
December 4, 2025
Foley Viewpoints
FDA Guidance on Biosimilars Highlights Glycosylation Profiling and Increases the Strategic Value of Patents Covering Antibodies Defined by Glycosylation
FDA’s September 2025 guidance requires detailed characterization of posttranslational modifications (PTMs), particularly glycosylation,…
December 2, 2025
Foley Viewpoints
CARB Climate Disclosure Laws Updates: CARB Enforcement Advisory for SB 261 and Docket Opening; Expected Deadline for SB 253
On December 1, 2025, the California Air Resources Board (CARB) provided multiple updates regarding its implementation of Senate Bill (SB)…